| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Myriad Genetics, Inc. (MYGN) has 9 insiders with recent SEC Form 4 filings, including 0 buys and 18 sells. MYGN is classified in the Life Sciences Tools & Services industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 1.07M | $4.81M | - | |
| Other | 573.4K | $2.58M | - | |
| COO | 381.8K | $1.72M | - | |
| Other | 251.9K | $1.13M | - | |
| Other | 170.2K | $765.8K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 11, 2018 | Capone Mark Christopher | President &C.e.o. | Sale+OE | 80,000 | $41.00 | $3,280,000.00 | -10.7% | |
| Jun 18, 2018 | Lanchbury Jerry S81 | Chief Scientific Officer | Sale+OE | 60,000 | $40.12 | $2,407,200.00 | -17.8% | |
| Jun 18, 2018 | Marsh Richard M | E.v.p., General Counsel | Sale+OE | 33,000 | $40.00 | $1,320,000.00 | -21.0% | |
| Jun 8, 2018 | Langer Dennis63 | Director | Sale+OE | 20,369 | $39.35 | $801,594.13 | -14.6% | |
| Jun 6, 2018 | Gilbert Walter Phd | Director | Sale+OE | 30,000 | $39.69 | $1,190,588.78 | -35.5% | |
| Jun 5, 2018 | Langer Dennis63 | Director | Sale+OE | 49,631 | $39.30 | $1,950,276.90 | -23.8% | |
| May 30, 2018 | Capone Mark Christopher | President &C.e.o. | Sale+OE | 90,000 | $38.00 | $3,420,000.00 | -21.3% | |
| May 30, 2018 | Marsh Richard M | E.v.p., General Counsel | Sale+OE | 33,139 | $38.00 | $1,259,282.00 | -21.1% | |
| May 30, 2018 | Langer Dennis63 | Director | Sale+OE | 10,000 | $37.92 | $379,245.00 | -20.1% | |
| May 21, 2018 | Langer Dennis63 | Director | Sale+OE | 10,000 | $35.90 | $359,000.00 | -20.1% |